Most Read Articles
Natalia Reoutova, 5 days ago

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Pearl Toh, 28 Aug 2019
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Audrey Abella, 28 Aug 2019
A pooled analysis of six trials failed to show noninferiority of a 3-month regimen to a 6-month regimen of oxaliplatin-based chemotherapy for patients with high-risk, stage II colorectal cancer (CRC).

Low muscle mass ups risk of recurrence, death after radical prostatectomy in prostate cancer patients

18 Aug 2019
Prostate cancer is a silent killer. Many may not be aware of the illness until it is too late.

There appears to be an association between low muscle mass and increased risks of recurrence and mortality in patients who undergo radical prostatectomy of prostate cancer regardless of the body mass index (BMI), suggests a recent study.

The 10-year distant metastasis-free survival rates in the lowest, second, third and highest psoas muscle index quartiles were 72.5 percent, 83.8 percent, 92.3 percent and 93.7 percent (p<0.001), respectively, while the 10-year cancer-specific survival rates were 85.7 percent, 92.1 percent, 96.8 percent and 97.6 percent. The corresponding 10-year overall survival rates were 74.5 percent, 79.6 percent, 89.8 percent and 90.6 percent (p<0.001 for each).

Moreover, the psoas muscle index was positively associated with BMI, serum concentrations of IGFBP-3 and bioavailable testosterone, and inversely associated with patient age, serum SHBG concentration and the neutrophil-to-lymphocyte ratio. Multivariable analysis revealed the association of the psoas muscle index with increased risks of biochemical recurrence, distant metastasis, and cancer-specific and overall mortality.

“Large-scale prospective studies are warranted [to confirm these findings],” the authors said.

This study was a retrospective examination of the association between muscle mass and survival following radical prostatectomy in patients with prostate cancer. Records of 2,042 patients who underwent radical prostatectomy of prostate cancer between 1998 and 2013 were reviewed. The psoas muscle index was measured on preoperative computerized tomography images to assess muscle mass.

Muscle mass has been associated with survival in patients with various types of solid tumours, according to the authors, and this investigation further elucidates the relationship between muscle mass and survival in patients with prostate cancer.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 5 days ago

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Pearl Toh, 28 Aug 2019
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Audrey Abella, 28 Aug 2019
A pooled analysis of six trials failed to show noninferiority of a 3-month regimen to a 6-month regimen of oxaliplatin-based chemotherapy for patients with high-risk, stage II colorectal cancer (CRC).